RxDoctor Payments DataLook up a doctor →

Marium Ilahi, MD

Endocrinology, Diabetes & Metabolism · Omaha, NENPI 1003020645

Payments from drug & device makers

$169,693in general payments, 2019–2025

Across 799 payments — averaging $212.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$93K
  • Bayer$41K
  • Novo Nordisk$29K
  • Lilly USA, LLC$939
  • Abbott$830
  • Mannkind Corporation$694
  • plus $5K from 42 others

What the payments were for

  • Speaking & faculty fees$149,91688%
  • Travel & lodging$6,9374%
  • Food & beverage$12,6827%
  • Education$990%
  • Gifts$590%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$169,693 in reported general payments places this provider in the 80th percentile of 43 endocrinology, diabetes & metabolism providers in Nebraska.

See all endocrinology, diabetes & metabolism providers in Nebraska

Medicare billing

Part B allowed, 2024
$216,538
Medicare patients
444
Services billed
5,988

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide228$406,253
TrulicityDulaglutide247$342,620
JardianceEmpagliflozin228$271,480
MounjaroTirzepatide187$253,636
Tresiba Flextouch U-200Insulin Degludec162$232,369
KerendiaFinerenone152$185,046
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog126$142,609
FarxigaDapagliflozin Propanediol132$138,117
RybelsusSemaglutide67$108,201
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/745$81,893
Humalog Kwikpen U-200Insulin Lispro25$70,284
Fiasp FlextouchInsulin Aspart (Niacinamide)64$68,712
Humulin R U-500 KwikpenInsulin Regular, Human45$65,096
Tresiba Flextouch U-100Insulin Degludec70$48,669
Novolog FlexpenInsulin Aspart97$38,761

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro, Humalog$939$606,858466 claims
Novo NordiskOzempic, Rybelsus, Novolog$29,142$526,773335 claims
Boehringer IngelheimJardiance, Tradjenta$507$286,972247 claims
BayerKerendia$40,922$185,046152 claims
AstraZenecaFarxiga$309$138,117132 claims
Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus, Admelog$481$24,08773 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$43$4,189491 claims
AbbVieSynthroid$36$4,13644 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 43 endocrinology, diabetes & metabolism providers in Nebraska.

Other endocrinology, diabetes & metabolism in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →